logo-loader

Rhinomed Limited in halt on European sales of snoring product

Published: 21:30 14 May 2015 BST

au_europe_map350_55540f8657c7e

Rhinomed Limited (ASX:RNO) has been granted an ASX trading halt in relation to European sales of its Mute over-the-counter snoring product.

The halt will last until the earlier of the announcement being made or the start of trade on Monday, 18th May 2015.

In April, the company expand its Australian wholesale pharmacy distribution footprint with Sigma Pharmaceuticals Limited (ASX:SIP) to include Mute.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

1 hour, 23 minutes ago